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Background: A temporary ileostomy may reduce symptoms from anastomotic leakage after rectal cancer
resection. Earlier results of the EASY trial showed that early closure of the temporary ileostomy was
associated with significantly fewer postoperative complications. The aim of the present study was to
compare health-related quality of life (HRQOL) following early versus late closure of a temporary
ileostomy.
Methods: Early closure of a temporary ileostomy (at 8–13 days) was compared with late closure (at more
than 12 weeks) in a multicentre RCT (EASY) that included patients who underwent rectal resection
for cancer. Inclusion of participants was made after index surgery. Exclusion criteria were signs of
anastomotic leakage, diabetes mellitus, steroid treatment, and signs of postoperative complications
at clinical evaluation 1–4 days after rectal resection. HRQOL was evaluated at 3, 6 and 12 months
after resection using the European Organisation for Research and Treatment of Cancer (EORTC)
questionnaires QLQ-C30 and QLQ-CR29 and Short Form 36 (SF-36®).
Results: There were 112 patients available for analysis. Response rates of the questionnaires were 82–95
per cent, except for EORTC QLQ-C30 at 12 months, to which only 54–55 per cent of the patients
responded owing to an error in questionnaire distribution. There were no clinically significant differences
in any questionnaire scores between the groups at 3, 6 or 12 months.
Conclusion: Although the randomized study found that early closure of the temporary ileostomy was
associated with significantly fewer complications, this clinical advantage had no effect on the patients’
HRQOL. Registration number: NCT01287637 (https://www.clinicaltrials.gov).
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Introduction
Low anterior resection with total mesorectal excision is
regarded as one of the optimal surgical treatments for
potentially curable carcinoma of the rectum1,2. Because
of the low anastomosis close to the pelvic floor, patients
often receive a temporary ileostomy at the time of the
resection to reduce the risk of symptomatic anastomotic
dehiscence3 and its clinical consequences3–6. However,
studies4,7–9 have reported considerable morbidity related
to the temporary ileostomy, with complication rates of up
to 50 per cent. Most patients with a temporary ileostomy
have the stoma for at least 3 months, and it is not unusual
for it to be left in place much longer. For some patients the
stoma becomes permanent10.
Data regarding quality of life (QOL) in patients receiving
a diverting stoma as part of their rectal cancer treatment
are limited11–14. In prospective studies it has been sug-
gested that patients with a stoma may suffer from impaired
health-related quality of life (HRQOL)15, which may
improve at stoma closure2. Complications such as stoma
leakage, parastomal skin irritation, dietary restrictions,
retraction and prolapse of the stoma have been reported
to have significant impact on the patient’s daily life12.
© 2017 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. BJS 2018; 105: 244–251
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The aim of the present study was to compare HRQOL
at 3, 6 and 12 months after rectal resection for cancer in a
multicentre RCT comparing early versus late closure of a
temporary ileostomy (EASY trial)16,17.
Methods
The EASY trial was designed as a randomized multicentre
trial16 comparing early with late closure of a temporary
ileostomy regarding risk of complications. Screening for
and inclusion of participants was made after index surgery
(total mesorectal excision for rectal cancer including cre-
ation of a temporary ileostomy). Exclusion criteria were
diabetes mellitus, ongoing steroid treatment, signs of
postoperative complications at clinical evaluation 1–4 days
after rectal resection and inability to understand the Dan-
ish or Swedish language. Patients with no adverse signs
were invited to participate and, after informed consent,
underwent further investigation with contrast-enhanced
CT or a flexible endoscopy of the rectum, or both, per-
formed 6–8 days after stoma creation to ensure that no
patient with signs of anastomotic leakage was included.
Patients were randomized to either the intervention group
with early closure (day 8–13 after stoma creation) or the
control group with late closure (more than 12 weeks after
stoma creation) of the ileostomy.
The primary endpoint of the study was the mean num-
ber of complications after rectal resection and up to 12
months; these results have been published previously17.
The present paper reports the secondary endpoints,
HRQOL and QOL, at 3, 6 and 12 months after the index
operation.
The study was approved in Denmark by the Science
Ethics Committee for the Capital Region (H-1-2010-113)
and in Sweden by theRegional Ethics Approval Committee
in Göteborg (Dnr 064-2011). Before inclusion, patients
were informed about the study and all participating patients
returned a signed consent form.
The project was approved by theData Protection Agency
in Denmark, and by the Personal Data Representative at
Sahlgrenska University Hospital, Göteborg, Sweden.
The protocol was registered at https://www.clinicaltrials
.gov (NCT01287637) before patient inclusion.
Patients
Eight hospitals in Denmark and Sweden participated in
the study, but three centres (with a total of 8 patients)
were excluded as they failed to maintain a screening log.
Consenting patients were asked to complete question-
naires at 3, 6 and 12 months after stoma creation (rectal
resection). The questionnaires included the 36-item Short
Form 36 (SF-36®; Rand Corporation, Santa Monica,
California, USA) and the European Organisation for
Research and Treatment of Cancer Quality of Life Ques-
tionnaire (EORTC QLQ) CR29 and C30. Data regarding
demographic details, tumour stage and height, chemora-
diotherapy and all complications within 12 months of
surgery were registered in case report forms.
Randomization
Consenting patients who fulfilled the inclusion crite-
ria were randomized either to the intervention group
with early closure of the ileostomy or to the control
group with late closure. Randomization was executed in
computer-generated blocks of six. The randomization
was performed on the surgical ward using sequentially
numbered thick, opaque and sealed envelopes. Blinding of
the intervention was not possible.
Health-related quality-of-life instruments
Short Form 36
SF-36® is a generic tool that evaluates patients’
self-reported quality of life18,19. It consists of 36 items
that measure eight dimensions of health on a multi-item
scale, including social and physical function. The scoring
scale ranges from 0 to 100, with lower scores indicating
worse health. The instrument has been validated, and for
comparison in this study a Swedish reference population
was used20.
EORTC QLQ-C30 and QLQ-CR29
The EORTC QLQ-C30 is a questionnaire developed to
assess QOL in patients with cancer, and consists of five
functional scales (physical, role, cognitive, emotional and
social), three symptom scales (fatigue, pain and nausea,
and vomiting), one global health status and QOL scale,
and six single-item measures (dyspnoea, insomnia, appetite
loss, constipation, diarrhoea and financial difficulties)21. A
high score on the functional scale represents a high level
of functioning, whereas a high score on the symptom scale
represents a high level of symptoms.
The EORTC QLQ-CR29 was designed for use in
patients undergoing treatment for colorectal cancer. It was
derived from the EORTC QLQ-C38 questionnaire, as
there was a need for an update in the colorectal module22.
The questions assess disease symptoms, side-effects of
treatment, body image, future perspective, and sexual
function and interest. Both questionnaires have been
validated internationally and were available in Danish and
Swedish versions22,23.
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 244–251
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Randomized
n = 127
Allocated to early closure n = 55
 Centre 1 n = 14
 Centre 2 n = 4
 Centre 3 n = 5
 Centre 4 n = 9
 Centre 5 n = 23
Follow-up§
 3 months n = 52
 6 months n = 50–52
 12 months n = 30–50
Died from rectal cancer# n = 1 Died from rectal cancer** n = 1
Follow-up¶
 3 months n = 51–53
 6 months n = 53
 12 months n = 31–47
Allocated to late closure n = 57
 Centre 1 n = 15
 Centre 2 n = 5
 Centre 3 n = 5
 Centre 4 n = 11
 Centre 5 n = 21
Excluded n = 15
 Centre failed to maintain screening log n = 8†
 Patient withdrew consent n = 3
 Other n = 4‡
Did not meet inclusion criteria n = 291
 Suspected anastomotic leakage n = 37
 Unwilling to participate n = 53
 Excluded for medical reasons n = 159*


























Fig. 1 Participant flow diagram, as in the EASY trial17. *Paralytic ileus (24), Hartmann procedure with intersphincteric dissection (16),
delayed postoperative recovery (15), perioperative complications (7), other infection (5), reoperation (7), high stoma output (5),
pulmonary embolism (1), ulcerative colitis (1), extensive cancer disease (3), cardiovascular disease (2), language difficulty (5), diabetes
(28), permanent or no stoma (29), steroid treatment (3), other (8). †Centre 6 (2), centre 7 (3), centre 8 (3). ‡Allocated to early closure,
but not possible to perform surgery within 8–13 days (1); early closure outside the study (2); randomized, but no further information
available (1). §3 months: Short Form 36 (SF-36®) (52), European Organisation for Research and Treatment of Cancer (EORTC)
QLQ-C30 (52), EORTC QLQ-CR29 (52); 6 months: 3 months: SF-36® (52), EORTC QLQ-C30 (50), EORTC QLQ-CR29 (50); 12
months: 3 months: SF-36® (50), EORTC QLQ-C30 (30), EORTC QLQ-CR29 (50). ¶3 months: SF-36® (53), EORTC QLQ-C30
(51), EORTC QLQ-CR29 (52); 6 months: 3 months: SF-36® (53), EORTC QLQ-C30 (53), EORTC QLQ-CR29 (53); 12 months:
SF-36® (47), EORTC QLQ-C30 (31), EORTC QLQ-CR29 (47). #Missing from follow-up at 12 months. **Patient did not have
closure; missing from follow-up at 12 months
All questionnaires were administered at 3, 6 and 12
months after stoma creation.
Statistical analysis
The study was part of a RCT with power calculated for the
primary endpoint. Group sizes in the EASY trial were set to
72 patients per group to evaluate complication rates16,17. In
Krouse et al.24 a minimally important difference of 8 units
was used for the different scales of SF-36®. Physical and
mental component scores had a standard deviation (s.d.) of
up to 15 units, and the eight specific scales had s.d. values
in the range 17–33. With group sizes of 72 or 55 and a s.d.
of 17 or 15 respectively, there will be 80 per cent power to
detect a true difference of 8 units.
The questionnaires SF-36®25, EORTC QLQ-C3026
and QLQ-CR2923 were scored according to the methods
recommended by the developers; missing data were han-
dled as instructed in the scoring manuals. Before analysis,
based on the literature and previous data, the authors
chose to present the functional scales and global health
status/QOL of the EORTC QLQ-C30 questionnaire,
and the functional scales (urinary frequency, stool fre-
quency and body image) of the EORTC QLQ-CR29
questionnaire. At 12-month follow-up, several patients (20
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 244–251
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Table 1 Baseline and preoperative characteristics of patients randomized to early or late closure
Early closure (n = 55) Late closure (n = 57)
Age (years)* 67 (36–82) 67 (39–81)
Sex ratio (F : M) 31 : 24 21 : 36
BMI (kg/m2)* 24 (17–32) 23 (19–35)
Co-morbidity 23 (42) 24 (42)†
Ischaemic heart disease 5 8
Hypertension 17 13
COPD 2 2
Renal disease 0 0
Other 9‡ 4§
Radiotherapy 16 (29) 16 (28)
Long-term 5 (9) 5 (9)
Adjuvant chemotherapy 22 (40) 23 (40)
Marital status
Single 5 (9) 9 (16)
Married 42 (76) 43 (75)
Widowed 8 (15) 5 (9)
Higher education 34 (62) 37 (65)
Employed
Yes 25 (45) 25 (44)
No 29 (53)¶ 32 (56)
Smoker 6 (11) 4 (7)
No. of pack years* 30 (16–30)# 26 (20–50)¶
Alcohol intake > 60 g/day 0 (0) 0 (0)¶
Lower border of tumour (cm from anal verge)
5–9 27 (49) 24 (42)
10–15 27 (49) 33 (58)
> 15 1 (2) 0 (0)
UICC clinical stage**
I 12 (22) 19 (33)
II 21 (38) 13 (23)
III 18 (33) 20 (35)
IV 3 (5) 1 (2)
Method of evaluation of anastomosis before ileostomy closure
CT 14 (25) 19 (33)
Rectoscopy 14 (25) 10 (18)
CT + rectoscopy 27 (49) 28 (49)
Total length of hospital stay††(days) * 14 (11–42) 14 (7–44)
Values in parentheses are percentages unless indicated otherwise; *values are median (range). †Data missing for two patients. ‡Asthma (2), depression (1),
idiopathic thrombocytopenic purpura (1), lymphoma (1), Waldenström’s macroglobulinaemia (1), osteoporosis (1), Sjögren syndrome (1), thyrotoxicosis
(1). §Depression (1), hyperlipidaemia (1), hypothyroidism (1), meningioblastoma (1). ¶Data missing for one patient. #Data missing for three patients.
**Data missing for one patient in each group; in addition, three patients in the late closure group had T0 N0 M0 disease and were therefore not classified.
††For both index surgery and loop ileostomy closure. COPD, chronic obstructive pulmonary disease; UICC, International Union Against Cancer. Table
reproduced with permission fromWolters Kluwer Health Inc. Danielsen AK, Park J, Jansen JE, Bock D, Skullman S, Wedin A et al. Early closure of a
temporary ileostomy in patients with rectal cancer: a multicenter randomized controlled trial. Ann Surg 2017; 265 (2): 284–290. https://journals.lww
.com/annalsofsurgery/.
in the intervention group and 16 in the control group)
were, by mistake, given an incomplete questionnaire in
which questions 16–30 of the EORTC QLQ-C30 were
missing. Before analysis, the decision was made to include
physical and role functioning, as these functional scales
are scored using questions 1–15 in accordance with the
EORTC manual. No other scales or items were analysed
for these patients in the EORTC QLQ-C30 at 12-month
follow-up. However, EORTC QLQ-CR29 and SF-36®
were analysed at 12-month follow-up. As the distribution
of the incomplete questionnaires was independent of the
observable characteristics of the patients who received
them, interpreting the missing data as being completely
random is reasonable and imputation was considered
unnecessary.
Owing to the characteristics of the data, the different
scales of SF-36® andEORTCwere summarized bymedian
(i.q.r.) values, and group comparisons were made using
the Wilcoxon rank sum test and the two-sample Hodges–
Lehmann estimator.
SF-36® scores were compared with those in a gen-
eral Swedish reference population20. For each of the
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 244–251
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Table 2 SF-36® scores at 3, 6 and 12 months after rectal resection
3 months 6 months 12 months
Median (i.q.r.) H–L* P† Median (i.q.r.) H–L* P† Median (i.q.r.) H–L* P†
Physical functioning
Early 90 (75–95)
0 (−5, 5) 0⋅646
90 (81⋅7–100)
0 (−5, 5) 0⋅630
95 (70–100)
0 (0, 5) 0⋅322
Late 90 (80–95) 90 (80–95) 95 (90–100)
Role physical
Early 75 (50–96⋅9)
12⋅5 (0, 18⋅8) 0⋅025
81⋅3 (50–100)
6⋅3 (0, 18⋅8) 0⋅140
81⋅3 (56⋅3–100)
0 (−6⋅3, 6⋅3) 0⋅718
Late 62⋅5 (43⋅8–75) 75 (50–93⋅8) 87⋅5 (75–100)
Bodily pain
Early 80 (52–100)
0 (−10, 0) 0⋅858
74 (62–100)
0 (−16, 0) 0⋅264
79 (51–100)
0 (0, 20) 0⋅035
Late 74 (62–100) 84 (63–100) 100 (74–100)
General health
Early 71⋅6 (52–88⋅5)
−5 (−15, 2) 0⋅139
77 (56–87)
0 (−10, 5) 0⋅820
74⋅5 (45–92)
5 (−5, 16⋅8) 0⋅279
Late 77 (67–87) 77 (65–87) 82 (72–87)
Vitality
Early 62⋅5 (43⋅8–81⋅3)
4⋅2 (−6⋅3, 12⋅5) 0⋅441
68⋅8 (50–81⋅3)
0 (−12⋅5, 6⋅3) 0⋅796
68⋅8 (50–81⋅3)
6⋅3 (0, 12⋅5) 0⋅196
Late 68⋅8 (56⋅3–81⋅3) 68⋅8 (56⋅3–81⋅3) 75 (62⋅5–87⋅5)
Social functioning
Early 75 (62⋅5–100)
0 (−12⋅5, 0) 0⋅468
87⋅5 (62⋅5–100)
0 (0, 0) 0⋅976
87⋅5 (62⋅5–100)
0 (0, 12⋅5) 0⋅415
Late 87⋅5 (75–100) 87⋅5 (62⋅5–100) 100 (75–100)
Role emotional
Early 83⋅3 (58⋅3–100)
0 (0, 8⋅3) 0⋅345
87⋅5 (66⋅7–100)
0 (0, 0) 0⋅923
95⋅8 (66⋅7–100)
0 (0, 0) 0⋅697
Late 83⋅3 (50–100) 83⋅3 (75–100) 95⋅8 (75–100)
Mental health
Early 80 (55–90)
5 (−5, 10) 0⋅217
80 (60–90)
−5 (−10, 5) 0⋅291
80 (60–90)
10 (0, 15) 0⋅020
Late 85 (65–90) 85 (70–95) 85 (75–95)
Mental component score
Early 52⋅5 (40⋅7–58⋅6)
1 (−2⋅6, 5) 0⋅588
54⋅4 (42⋅8–58⋅6)
0⋅2 (−3, 3⋅9) 0⋅939
54⋅1 (42⋅6–58⋅5)
2⋅5 (−0⋅7, 6⋅3) 0⋅105





−0⋅2 (−3⋅6, 3) 0⋅900
54⋅1 (44⋅5–59)
1⋅6 (−1, 6⋅1) 0⋅281
Late 51⋅2 (46⋅9–54⋅8) 52⋅2 (45⋅8–57⋅9) 56⋅8 (51–59⋅4)
*Two-sample Hodges–Lehmann (H–L) estimator with 95 per cent asymptotic confidence limits in parentheses. SF-36®, Short Form 36. †Wilcoxon
rank sum test for difference between early and late closure.
eight scales, the individual levels were compared with
age-matched (17–34, 35–49, 50–64, and 65 or more
years) mean levels from the reference population. The
proportion of patients with values below the reference
levels was compared between the intervention and control
group using a χ2 test. The software packages SPSS® ver-
sion 23 (IBM, Armonk, New York, USA), SAS® version
9.4 (SAS Institute, Cary, North Carolina, USA) and R
version 3.2.327 were used for statistical analysis. Scores
for SF-36®, EORTC QLQ-C30 and QLQ-CR29 were
derived and summarized by median (i.q.r.) values.
Results
The EASY trial assessed 418 patients for eligibility. After
exclusion of 291 patients, 127 patients were randomized
(Fig. 1). A further 15 patients were excluded, eight from
three centres that were excluded from the study as they
failed tomaintain a screening log. In summary, 112 patients
were included from February 2011, with the last follow-up
in November 2015. Some 55 patients in the intervention
(early closure) group and 57 in the control (late closure)
group were available for analysis. There were no violations
of the randomization. Except for a larger proportion of
women in the intervention group, baseline demographic
characteristics and clinical data were similar in the two
groups (Table 1).
Questionnaire response rates were generally around 90
(range 82–95) per cent, excluding the EORTCQLQ-C30
at 12-month follow-up, owing to missing questions as
described in the Methods section (Fig. 1).
SF-36® scores were similar between the two groups,
with no differences in the physical component score or the
mental component score, but significant differences in role
physical, bodily pain and mental health at 3, 12 and 12
months respectively (Table 2). All dimensions in SF-36®
improved over time. At 3 months, a majority of patients
in both groups scored values below mean levels in the
reference population20, especially regarding role physical.
At 12 months, 52–85 per cent of the patients scored higher
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 244–251
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Table 3 EORTC QLQ-C30 scores at 3, 6 and 12 months after rectal resection
3 months 6 months 12 months
Median (i.q.r.) H–L* P† Median (i.q.r.) H–L* P† Median (i.q.r.) H–L* P†
Global quality of life
Early 75 (50–83⋅3)
0 (−8⋅3, 8⋅3) 0⋅941
66⋅7 (50–83⋅3)
0 (−8⋅3, 8⋅3) 0⋅961
83⋅3 (50–91⋅7)
0 (−16⋅7, 8⋅3) 0⋅889
Late 66⋅7 (58⋅3–83⋅3) 66⋅7 (66⋅7–83⋅3) 83⋅3 (66⋅7–91⋅7)
Physical functioning
Early 93⋅3 (73⋅3–100)
0 (0, 6⋅7) 0⋅634
93⋅3 (80–100)
0 (−6⋅7, 0) 0⋅433
93⋅3 (73⋅3–100)
0 (−13⋅3, 0) 0⋅137
Late 93⋅3 (73⋅3–100) 93⋅3 (80–100) 100 (80–100)
Role functioning
Early 83⋅3 (66⋅7–100)
−16⋅7 (−16⋅7, 0) 0⋅066
100 (66⋅7–100)
0 (0, 0) 0⋅503
100 (66⋅7–100)
0 (0, 0) 0⋅793
Late 66⋅7 (50–100) 83⋅3 (66⋅7–100) 100 (66⋅7–100)
Emotional functioning
Early 83⋅3 (66⋅7–100)
8⋅3 (0, 16⋅7) 0⋅023
83⋅3 (66⋅7–100)
−8⋅3 (−16⋅7, 0) 0⋅031
91⋅7 (66⋅7–100)
0 (−8⋅3, 0) 0⋅409
Late 91⋅7 (83⋅3–100) 91⋅7 (75–100) 91⋅7 (83⋅3–100)
Cognitive functioning
Early 100 (83⋅3–100)
0 (0, 0) 0⋅447
83⋅3 (83⋅3–100)
0 (−16⋅7, 0) 0⋅131
100 (66⋅7–100)
0 (0, 0) 0⋅652
Late 100 (83⋅3–100) 100 (83⋅3–100) 100 (83⋅3–100)
Social functioning
Early 83⋅3 (66⋅7–100)
0 (0, 0) 0⋅583
83⋅3 (66⋅7–100)
0 (0, 0) 0⋅882
83⋅3 (66⋅7–100)
0 (−16⋅7, 0) 0⋅142
Late 83⋅3 (66⋅7–100) 83⋅3 (66⋅7–100) 100 (66⋅7–100)
*Two-sample Hodges–Lehmann (H–L) estimator with 95 per cent asymptotic confidence limits in parentheses. EORTC, European Organisation for
Research and Treatment of Cancer. †Wilcoxon rank sum test for difference between early and late.
Table 4 EORTC QLQ-CR29 scores for selected functions at 3, 6 and 12 months after rectal resection
3 months 6 months 12 months
Median (i.q.r.) H–L* P† Median (i.q.r.) H–L* P† Median (i.q.r.) H–L* P†
Urinary frequency
Early 16⋅7 (0–33⋅3)
0 (0, 16⋅7) 0⋅323
16⋅7 (0–50)
0 (−16⋅7, 0) 0⋅353
16⋅7 (0–33⋅3)
0 (0, 16⋅7) 0⋅268
Late 16⋅7 (0–50) 16⋅7 (8⋅3–41⋅7) 33⋅3 (0–50)
Stool frequency
Early 33⋅3 (16⋅7–50)
33⋅3 (16⋅7, 33⋅3) < 0⋅001
33⋅3 (16⋅7–50)
16⋅7 (0, 33⋅3) 0⋅068
33⋅3 (16⋅7–50)
0 (0, 16⋅7) 0⋅611
Late 0 (0–16⋅7) 16⋅7 (0–66⋅7) 33⋅3 (16⋅7–50)
Body image
Early 88⋅9 (66⋅7–100)
0 (−11⋅1, 0) 0⋅715
88⋅9 (77⋅8–100)
0 (0, 11⋅1) 0⋅364
94⋅4 (77⋅8–100)
0 (0, 0) 0⋅502
Late 77⋅8 (66⋅7–100) 88⋅9 (66⋅7–100) 100 (88⋅9–100)
*Two-sample Hodges–Lehmann (H–L) estimator with 95 per cent asymptotic confidence limits in parentheses. EORTC, European Organisation for
Research and Treatment of Cancer. †Wilcoxon rank sum test for difference between early and late closure.
than the reference group, with physical functioning scoring
the highest among the dimensions.
EORTC QLQ-C30 and QLQ-CR29 scores were
comparable between intervention and control groups.
Emotional functioning was lower in the early closure
group at 3 and 6 months, but similar to the late closure
group at 12 months (Table 3). No statistically significant
differences were seen in the dimensions of the QLQ-CR29
questionnaire (Table 4).
Discussion
In this RCT no significant differences were observed
in HRQOL within 12 months after rectal resection for
cancer when early and late closure of temporary ileostomy
were compared. Global QOL generally improved later in
the follow-up period (6–12 months), and at 12 months
the results were comparable, not only between the two
groups but also with respect to both age-matched refer-
ence populations28,29 and previous findings30. Although
there was a tendency for improvement over time in
global QOL and role functioning, no clinically significant
changes were seen in QLQ-C30 scores. The definition of
a clinically significant change over time was based on the
suggestion31 that a difference of 5–10 points be consid-
ered a ‘little change’ and a difference of 10–20 points a
‘moderate change’. When comparing the SF-36® scores
with Swedish reference data20, a general improvement was
seen during the follow-up interval.
© 2017 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2018; 105: 244–251
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No baseline data for preoperative assessment were avail-
able, owing to the fact that the patients were enrolled and
randomized after the rectal resection. This is considered
a weakness in the evaluation of HRQOL. Even though
reference data were available, there was no opportunity
to investigate the development and changes in HRQOL
from preoperative to postoperative values. In addition,
considering the length of time needed for recovery after
rectal cancer surgery, follow-up at 18 and 24 months might
have been of value to observe any further development and
potential improvement in HRQOL.
The lack of difference between the two groups dif-
fers somewhat from the findings of previous prospective
studies2,13, which have reported that patients with a tempo-
rary stoma may suffer from impaired HRQOL in compar-
ison with patients who had undergone a similar operation
but without a covering stoma, such as a high anterior
resection. However, the results of previous studies are con-
tradictory. A Danish study32 suggested that a temporary
stoma left patients with feelings of uncertainty, that closure
of the stoma was seen as a crucial event, and that knowing
the date for closure was important. A prospective study11
found improved global QOL following stoma reversal
after low anterior resection for rectal cancer, and physical
function, as measured by both the QLQ-C30 and SF-36®
questionnaires, was also significantly improved.However, a
prospective interview study14 reported no change in QOL
following closure of a temporary stoma after rectal cancer
surgery, and the patient’s personality rather than clinical
variables has a strong and lasting influence on QOL33. As
suggested in a review article34 from 2011, closure of the
stoma and prompt redirection of intestinal contents to the
rectum 3–6 months after rectal resection might be consid-
ered to be a cause of negative impact on patients’ physical,
social and psychological health for several months. Gastro-
intestinal symptoms, such as increased stool frequency,
urgency, diarrhoea and persistent problems including
low anterior resection syndrome, do not occur in the
presence of a temporary stoma. Consequently, stoma
reversal might result in the appearance of these symptoms.
Although this was not observed in the present study, this
could be because of the small size of the cohort. In the
COLOR II trial35, patients with rectal cancer appeared
to need a longer time to recover compared with those
with colonic cancer. This could perhaps explain the lack
of difference between the groups in the present study, as
both involved extensive surgery for rectal cancer, where
timing of the stoma closure is not reflected in the HRQOL
follow-up.
The EASY trial17 found that it was safe and advantageous
to close the loop ileostomy early in patients with no clinical
or radiological signs of anastomotic leakage. However, the
present study did not find a link between this clinical
advantage and patients’ HRQOL.
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